Active Filter(s):
Details:
iBio will manufacture 10 proteins to be tested in the production of Safi’s cell therapies as part of the first Statement of Work. Safi will have the option to designate certain proteins as proprietary to their bioprocess, but iBio will have rights to market all other products.
Lead Product(s): Blood cell therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: iBio
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Agreement October 02, 2020